ASBP News & Events

Aspire Biopharma wholly owned subsidiary, Buzz Bomb Caffeine Company, announced a strategic brand management and distribution agreement with Blue Shark Beverages. Effective February 1, the relationship is expected to drive the retail expansion of BUZZ BOMB, a proprietary 50mg sublingual caffeine stick pack in four flavors, across key Southern California markets. The rollout will debut in Palm Springs and surrounding cities in the Coachella Valley, followed by a phased expansion into the Los Angeles and San Diego metropolitan areas.

Aspire Biopharma has entered into an agreement with Microsize. Microsize specializes in particle size reduction, micronization, and solubility enhancement for drugs. Aspire has partnered with Microsize to support the ongoing development of its lead drug candidate: acetylsalicylic acid 162 mg sublingual powder, an investigational new drug undergoing development for the emergency treatment of suspected acute myocardial infarction. This collaboration is expected to deliver optimized drug product to support an upcoming clinical trial and the planned submission of a Section 505(b)(2) New Drug Application for Aspire's sublingual aspirin near the end of 2026. The clinical trial will evaluate serum thromboxane B2 inhibition in 32 healthy volunteers, comparing (162 mg) against the current standard of care-two chewed 81 mg aspirin tablets. This collaboration marks a critical step for Aspire, securing critical expertise to support its ongoing and future product development and regulatory efforts.

Aspire Biopharma announced the filing of a new provisional patent application with the United States Patent and Trademark Office. The application, titled "A Sublingual Powder Formulation of Clopidogrel and Methods of Use Thereof," covers the first-ever sublingual formulation of clopidogrel, the active pharmaceutical ingredient in the widely prescribed blood thinner Plavix. This development represents a series of sublingual-based therapeutic alternatives the Company intends to commercialize via the FDA's 505(b)(2) regulatory pathway. Aspire's strategic pipeline focuses on reformulating approved generic therapeutics to address unmet needs where no sublingual alternatives currently exist, thus bringing the benefits of reducing or eliminating gastric irritation to products with these known side effects.

Aspire Biopharma has taken delivery of two million units of its flagship caffeine supplement, BUZZ BOMB. The company said, "This delivery marks a critical milestone in Aspire's commercialization strategy, introducing a comprehensive brand relaunch and redesigned packaging. The new aesthetic is engineered for high-impact shelf presence and digital engagement, emphasizing the product's core advantages: nearly instant energy, precise 50mg dosing, and the convenience of sublingual absorption."